NCT05641831View on ClinicalTrials.gov

Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study

PHASE2RecruitingINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

February 6, 2023

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions
Clonal Cytopenia of Undetermined Significance
Interventions
PROCEDURE

Biospecimen Collection

Undergo peripheral blood collection

PROCEDURE

Bone Marrow Aspiration and Biopsy

Undergo bone marrow biopsy and aspiration

DRUG

Canakinumab

Given SC

PROCEDURE

Chest Radiography

Undergo chest x-ray

PROCEDURE

Echocardiography

Undergo ECHO

DRUG

Placebo Administration

Given SC

OTHER

Quality-of-Life Assessment

Ancillary studies

Trial Locations (6)

10021

RECRUITING

Weill Cornell Medical College, New York

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

33136

RECRUITING

University of Miami, Miami

37232

RECRUITING

Vanderbilt University Medical Center, Nashville

43210

RECRUITING

Ohio State University Comprehensive Cancer Center, Columbus

75235

RECRUITING

UT Southwestern Medical Center at Dallas, Dallas

All Listed Sponsors
lead

Uma Borate

OTHER